<?xml version="1.0" encoding="UTF-8"?>
<p id="Par28">At present, trivalent and quadrivalent formulations are available, which include an H1N1 strain, an H3N2 strain and one or two Influenza B strains belonging to evolutionarily diverging lineages – B/Victoria or B/Yamagata. The estimated protection of these vaccines is roughly about 60% in adults and 83% in children [
 <xref ref-type="bibr" rid="CR24">24</xref>]. Efforts are underway for production of the “universal” influenza vaccine which are not dependent on this annual labor intensive matching but target certain protein regions common to the seasonal and pre-pandemic strains. The two leading candidates for universal vaccines include the highly conserved stem region of the HA and the M2 protein [
 <xref ref-type="bibr" rid="CR25">25</xref>].
</p>
